busulfan has been researched along with B-Cell Chronic Lymphocytic Leukemia in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " BU, given as four single daily doses of 150 mg/m2, is appropriate and safe in all age groups of children." | 2.71 | Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages. ( Berry, A; Earl, JW; Nath, C; Shaw, PJ, 2004) |
| "Although chronic lymphocytic leukemia (CLL) remains an incurable disease with standard chemotherapy, the appropriate role and timing of transplantation are unclear." | 1.33 | Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. ( Alyea, EP; Antin, JH; Brown, JR; Cutler, C; Fisher, DC; Gribben, JG; Ho, V; Kim, HT; Lee, SJ; Li, S; Milford, EL; Ritz, J; Soiffer, RJ; Stephans, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersen, NS | 1 |
| Bornhäuser, M | 3 |
| Gramatzki, M | 1 |
| Dreger, P | 2 |
| Vitek, A | 1 |
| Karas, M | 1 |
| Michallet, M | 2 |
| Moreno, C | 1 |
| van Gelder, M | 1 |
| Henseler, A | 1 |
| de Wreede, LC | 1 |
| Schönland, S | 1 |
| Kröger, N | 3 |
| Schetelig, J | 3 |
| Thiede, C | 2 |
| Schwerdtfeger, R | 2 |
| Kiehl, M | 2 |
| Beyer, J | 2 |
| Hensel, M | 2 |
| Scheffold, C | 2 |
| Ho, AD | 2 |
| Kienast, J | 2 |
| Neubauer, A | 2 |
| Zander, AR | 2 |
| Fauser, AA | 2 |
| Ehninger, G | 2 |
| Siegert, W | 2 |
| Brand, R | 1 |
| Hansz, J | 1 |
| Milligan, D | 1 |
| Corradini, P | 1 |
| Finke, J | 1 |
| Deliliers, GL | 1 |
| Martino, R | 1 |
| Russell, N | 1 |
| Van Biezen, A | 1 |
| Niederwieser, D | 1 |
| Sayer, HG | 1 |
| Held, TK | 1 |
| Hoffken, K | 1 |
| Shaw, PJ | 1 |
| Nath, C | 1 |
| Berry, A | 1 |
| Earl, JW | 1 |
| Brown, JR | 1 |
| Kim, HT | 1 |
| Li, S | 1 |
| Stephans, K | 1 |
| Fisher, DC | 1 |
| Cutler, C | 1 |
| Ho, V | 1 |
| Lee, SJ | 1 |
| Milford, EL | 1 |
| Ritz, J | 1 |
| Antin, JH | 1 |
| Soiffer, RJ | 1 |
| Gribben, JG | 1 |
| Alyea, EP | 1 |
| Hoogendoorn, M | 1 |
| Jedema, I | 1 |
| Barge, RM | 1 |
| van Luxemburg-Heijs, SA | 1 |
| Beaumont, F | 1 |
| Marijt, EW | 1 |
| Willemze, R | 1 |
| Falkenburg, JH | 1 |
1 review available for busulfan and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Disease-Free | 2003 |
1 trial available for busulfan and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
Topics: Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Disease-Free Survival; Drug Administ | 2004 |
5 other studies available for busulfan and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cy | 2019 |
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive | 2002 |
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Topics: Adult; Aged; Busulfan; Child; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Graf | 2003 |
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Di | 2006 |
Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neop | 2007 |